89bio, Inc. (ETNB)
- Previous Close
8.25 - Open
8.30 - Bid 8.29 x 100
- Ask 8.37 x 200
- Day's Range
8.19 - 8.45 - 52 Week Range
6.57 - 22.93 - Volume
86,020 - Avg. Volume
1,280,411 - Market Cap (intraday)
792.27M - Beta (5Y Monthly) 0.95
- PE Ratio (TTM)
-- - EPS (TTM)
-2.00 - Earnings Date May 2, 2024 - May 6, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
31.89
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.
www.89bio.comRecent News: ETNB
Performance Overview: ETNB
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ETNB
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ETNB
Valuation Measures
Market Cap
785.60M
Enterprise Value
233.84M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
1.46
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-1.75
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-23.83%
Return on Equity (ttm)
-41.33%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-142.19M
Diluted EPS (ttm)
-2.00
Balance Sheet and Cash Flow
Total Cash (mrq)
578.87M
Total Debt/Equity (mrq)
5.05%
Levered Free Cash Flow (ttm)
-82.55M